E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
Bristol-Myers Squibb Co.  
Bristol-Myers Squibb Co.
BMYLast: $26.38 ($+0.35)Volume: 12,234,117Last Trade: 8/5/2010 4:21:12 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NYSE:BMY $26.38 ($+0.35 +1.3446%)
Industry: Health Sector: Pharmaceuticals
Open: 25.83 Previous Close: 26.03
Day's High: 26.38 Day's Low: 25.80
52-Week High: 32.35 52-Week Low: 21.75
 
Bid: 26.34 / 400 Ask: 26.40 / 200
Volume: 12,234,117 Outstanding: 1,978,511,425
Market Cap: $43 B
Bristol-Myers Squibb Co. Profile
Bristol-Myers Squibb, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare related products. Co. has three reportable segments: Pharmaceuticals, Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals, primarily an infant formula and children's nutritionals business. The Other Healthcare segment consists of ConvaTec and Medical Imaging businesses.
 Bristol-Myers Squibb Co. News & Press Releases

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented
Bristol-Myers Squibb Company ( BMY ) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further develop... [more]

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previ
Bristol-Myers Squibb Company ( BMY ) today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that... [more]

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to
Bristol-Myers Squibb Company ( BMY ) and Otsuka Pharmaceutical Co., Ltd. today announced Phase III study results in which SPRYCEL (dasatinib) 100 mg o... [more]

Bristol-Myers Squibb to Present Data on 13 Oncology Compounds During 2010 American Society of Clinic
Bristol-Myers Squibb Company ( BMY ), a global leader in oncology drug development, today announced that more than 95 scientific abstracts on 13 of its on... [more]

Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept
Bristol-Myers Squibb Company ( BMY ) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the... [more]

StockSource.us Reports MNDP - Breakout Penny Stock
( EMAILWIRE.COM , April 08, 2010 ) Del Mar, CA - Mundus Group (MNDP) and its subsidiary's are expecting a bumper year in 2010. The company which is an innovator and world leader in Unmanned Air Vehicles (UAV) and Remote Controlled Vertical Take Off an... [more]

LiquidStockReport.com Reports on Stocksource.us
( EMAILWIRE.COM , April 01, 2010 ) Del Mar, CA Stocksource.us is a full investor relations firm that seeks out innovative emerging companies and tell their story to qualified investors looking for ground floor opportunities. The compan... [more]

Investment overview released on Bristol-Myers Squibb (NYSE: BMY)
( CHARTPOPPERS.COM , March 25, 2010 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Bristol-Myers Squibb (NYSE: BMY) The Consolidated Investment Analysis on Bristol-Myers Squibb (NYSE: BMY)wil... [more]

LiquidStockReport.com Green Energy Live Looks at Solar Energy
( EMAILWIRE.COM , March 11, 2010 ) Del Mar, CA Green Energy Live Inc (GELV), the growing clean energy company is in the final stages of its second acquisition, that of Peck Electric, a leading supplier of electrical contracting services in Vermont. <... [more]

LiquidStockReport.com GELV Peck Solid & Well Run'
( EMAILWIRE.COM , March 11, 2010 ) Del Mar, CA - A company backing itself in the clean energy market is Green Energy Live Inc (GELV), a growing clean energy company with high expectations of its self. The company recently released news that it is in t... [more]

StockSource.us Reports Green Energy Live Moves Deeper into Energy Markets
( EMAILWIRE.COM , March 09, 2010 ) Del Mar, CA Green Energy Live Inc (GELV), has made its intentions clear in the last few weeks to further penetrate the clean energy market and develop biomass to energy solution for the U.S. Livestock Industry by up... [more]

ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superio
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company ( BMY ) and Pfizer Inc. ( PFE ), was statistically superior to 40... [more]

Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company ( BMY ) today declared a quarterly dividend of thirty-two cents ($0.32) per share on the $.10 par v... [more]

FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis o
Bristol-Myers Squibb Company ( BMY ) today announced that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee... [more]

Picksthatmove.com Provides Investment Opinion on Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer A
PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business... [more]

StockSource.us Reports Hot Penny Stock Pick GELV
( EMAILWIRE.COM , February 12, 2010 ) Del Mar, CA Green Energy Live Inc (GELV) the growing clean energy company is expanding its home base by moving its head office and bringing on more key staff members. This as it sees demand for green clean energy... [more]

LiquidStockReport.com GELV Strengthens Position
( EMAILWIRE.COM , February 12, 2010 ) Del Mar, CA Green Energy Live Inc.(GELV) the publicly listed engineering and technology company, is busy focusing on developing and commercializing renewable energy gasification systems to convert biomass wastes... [more]

StockSource.us Reports GELV Looking to Make its Mark
( EMAILWIRE.COM , February 11, 2010 ) Del Mar, CA The alternative energy field is a relatively new but constantly growing field. Advancements in biotechnology and material science are making clean energy an increasingly viable energy source. Green E... [more]

LiquidStockReport.com-GELV Positioned for Growth
( EMAILWIRE.COM , February 09, 2010 ) Del Mar, CA Green Energy Live Inc (GELV), the growing clean energy company, is looking to focus their energies into the biomass to energy market. GELV has decided to put plans for ethanol production on the back b... [more]

Chartpoppers.com releases Investment Analysis on Bristol Myers Squibb Co (NYSE: BMY)
( CHARTPOPPERS.COM , February 08, 2010 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Bristol Myers Squibb Co (NYSE: BMY) The Consolidated Investment Analysis on Bristol Myers Squibb Co (NYSE... [more]

Chartpoppers.com releases a Consolidated Investment Analysis on Bristol-Myers Squibb (NYSE: BMY)
( CHARTPOPPERS.COM , December 24, 2009 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Bristol-Myers Squibb (NYSE: BMY) The Consolidated Investment Analysis on Bristol-Myers Squibb (NYSE: BMY)... [more]

ADDING MULTIMEDIA Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Api
Bristol-Myers Squibb Company ( BMY ) and Pfizer ( PFE ) today announced that the companies are planning to submit an application for regulatory ap... [more]

Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Bristol-Myers Squibb Company ( BMY ) and Pfizer ( PFE ) today announced that the companies are planning to submit an application for regulatory ap... [more]

Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
Bristol-Myers Squibb Company ( BMY ) and Mead Johnson Nutrition Company ( MJN ) today announced that Bristol-Myers Squibb Company (“BMS”) has amended and exte... [more]

U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability
Bristol-Myers Squibb Company ( BMY ) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the... [more]

Bristol-Myers Squibb Announces Split-Off of Mead Johnson
Bristol-Myers Squibb Company ( BMY ) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off t... [more]

FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for
Bristol-Myers Squibb Company ( BMY ) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ ® ... [more]

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in He
Bristol-Myers Squibb Company ( BMY ) and ZymoGenetics, Inc. ( ZGEN ) today presented final results from a Phase 1b clinical trial of PEG-Interfero... [more]

BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of
Bristol-Myers Squibb ( BMY ) today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in whic... [more]

Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common
Exelixis, Inc. ( EXEL ) and Bristol-Myers Squibb Company ( BMY ) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in... [more]

Taisho (TYO:4535) Agreed to Buy Bristol-Myers (NYSE:BMY) Asian Assets For US$310M
Japan's Taisho Pharmaceutical Co. Ltd. (TYO:4535) said Wednesday it will buy Bristol-Myers Squibb Co.'s ( BMY ) over-the-counter drug assets worth US$310 million in Asia Pacific (excluding China and Japan). Under their agreement, Tais... [more]

Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in A
Bristol-Myers Squibb Company ( BMY ) today announced that it has reached an agreement for the sale of its OTC assets in Asia Pacific (excluding China and Japan... [more]

Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application
Bristol-Myers Squibb Company ( BMY ) announced today that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the company’s s... [more]

Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.
Bristol-Myers Squibb Company ( BMY ) announced today that it has completed its previously announced $2.4 billion acquisition of Medarex, Inc. ( MEDX ) (“Medar... [more]

New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of P
Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sano... [more]

Endocyte Says Collaboration Paying Off
Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company ( BMY ).... [more]

Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.
Bristol-Myers Squibb Company ( BMY ) announced today that it has extended its previously announced cash tender offer, through its wholly-owned subsidiary,... [more]

Zacks Analyst Blog Highlights: eBay Inc., ZymoGenetics, Inc., Bristol-Myers Squibb, Express Scripts,
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting sto... [more]

Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Onco
Bristol-Myers Squibb Company ( BMY ) today announced an agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter, “Otsuka”) to extend the U.S. portion of... [more]

Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atr
Bristol-Myers Squibb Company ( BMY ) today announced a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the develo... [more]

Technical Trade Alerts on market movers: CNO, SUN, IP, BMY, GILD, INTC
(EMAILWIRE.COM, March 04, 2009 ) DALLAS, Texas Beacon Equity Research announces the release of Trade Alerts covering market movers: Conseco Inc. (NYSE: CNO), Sunoco Inc. (NYSE: SUN), International Paper Co. (NYSE: IP), Bristol-Myers Squibb Co. (NYSE: B... [more]

Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company’s Executive Committee
Bristol-Myers Squibb Company ( BMY ) today announced a series of related organizational changes consistent with the company’s transformation to a next-generati... [more]

Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company ( BMY ) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value... [more]

Zacks Releases Four Powerful ''Buy'' Stocks: LaBranche & Co., Inc., Bristol Myers Squibb Co., TransD
Four free stock picks are being made available today on Zacks.com. The industry’s leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Z... [more]

Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepat
The Bristol-Myers Squibb Foundation today announced funding of more than $1.17 million, focused on hepatitis C prevention and education and the mitiga... [more]

ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplementa
ImClone Systems , a wholly-owned subsidiary of Eli Lilly and Company ( LLY ), and Bristol-Myers Squibb Company ( BMY ) today announced... [more]

Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound
Bristol-Myers Squibb Company ( BMY ) and ZymoGenetics, Inc. ( ZGEN ) today announced a global collaboration for PEG-Interferon lambda, a novel type 3 interf... [more]

Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company ( BMY ) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par v... [more]

New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metast
Bristol-Myers Squibb Company ( BMY ) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, incl... [more]

Zacks Releases Four Powerful ''Buy'' Stocks: Fuel Systems Solutions, Bristol-Myers Squibb Co., Carte
Four free stock picks are being made available today on Zacks.com. The industry’s leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Z... [more]

Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal
Sanofi-aventis ( SNY ) and Bristol-Myers Squibb Company ( BMY ) announced today that the American Heart Journal published the rationale and design of... [more]

New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by
Bristol-Myers Squibb Company ( BMY ) today announced data from two separate cohort evaluations, in which long-term treatment with BARACLUDE <span i... [more]

Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Qual
Bristol-Myers Squibb Company ( BMY ) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from... [more]

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA
Bristol-Myers Squibb Company ( BMY ) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid ar... [more]

96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (ataz
Bristol-Myers Squibb Company ( BMY ) today announced 96-week data from the CASTLE study, in which 74 percent of the 440 patients in the REYATAZ<span id="bwanpa... [more]

Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Respo
ImClone Systems Incorporated ( IMCL ) and Bristol-Myers Squibb Company ( BMY ) today announced the publication of study results showing that metas... [more]

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2008 on October 23
Bristol-Myers Squibb Company ( BMY ) will announce results for the third quarter of 2008 on Thursday, October 23. During a 10:30 a.m. (ET) conference call... [more]

U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Rit
Bristol-Myers Squibb Company ( BMY ) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ <span id="bwanp... [more]

Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share
Bristol-Myers Squibb Company ( BMY ) today announced that it is increasing its initial offer for ImClone Systems Incorporated ( IMCL ) and intends to commence a te... [more]

Bristol-Myers Squibb Announces Filing of IPO Registration Statement for Mead Johnson Nutrition Compa
Bristol-Myers Squibb Company ( BMY ) today announced that its wholly-owned subsidiary, Mead Johnson Nutrition Company , has filed a registration state... [more]

ImClone Systems Submits Letter to Bristol-Myers Squibb
ImClone Systems Incorporated ( IMCL ) announced today that Carl Icahn, Chairman of its Board of Directors, sent the following letter to James Cornelius,... [more]

Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line
ImClone Systems Incorporated ( IMCL ) and Bristol-Myers Squibb Company ( BMY ) today announced the publication of results from a Phase 3 trial in... [more]

New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Pati
Bristol-Myers Squibb Company ( BMY ) and Pfizer Inc ( PFE ) announced today the results of a Phase 2 dose-ranging study (APPRAISE-1) involving the investiga... [more]

Ingenuity Systems Announces Multi-Year Deal With Bristol-Myers Squibb for IPA
REDWOOD CITY, Calif. , Sept. 2 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced a multi-year agreement with... [more]

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
Bristol-Myers Squibb Company ( BMY ) and Pfizer Inc ( PFE ) provided an update on the apixaban clinical development program today. The companies announced t... [more]

ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students Ho
A laboratory experiment that demonstrates how easily disease can spread, procedures to assure the safety of medicines, and learning how clinical trials are conducted are among the many lessons teachers from seven school districts in four states will le... [more]

CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r
Please replace the release with the following corrected version due to multiple revisions. The corrected version reads: CASTLE DATA SHOWE... [more]

Dako Enters into Collaboration with Bristol-Myers Squibb for Pharmacodiagnostics
GLOSTRUP, DENMARK -- (MARKET WIRE) -- 06/27/08 -- Dako enters into collaboration with Bristol-Myers Squibb to develop clinical diagnostics to identify cancer patients who may receive greater benefits from certain drugs being developed by Bristol-Myers... [more]

Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated
Bristol-Myers Squibb Company ( BMY ) announced today that it has completed its previously announced $190 million acquisition of Kosan Biosciences Incorporated... [more]

Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company ( BMY ) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par v... [more]

ADDING MULTIMEDIA Newark High School Students and Research Scientists Discuss Challenges of Making M
More than 75 Newark high school students and teachers today probe the challenges and complexities of making medicines when they interact with research scientists... [more]

New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of C
Bristol-Myers Squibb Company ( BMY ) and Medarex, Inc. ( MEDX ) today announced preliminary survival data for ipilimumab (10 mg/kg monotherapy), an investigatio... [more]

ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advance
ImClone Systems Incorporated ( IMCL ) and Bristol-Myers Squibb Company ( BMY ) today announced results that show the addition of... [more]

Bristol-Myers Squibb Reaffirms 2008 Earnings Guidance
Bristol-Myers Squibb Company ( BMY ) today reaffirmed its 2008 earnings guidance for fully diluted earnings per share from continuing operations on a GAAP basis... [more]

Zacks Analyst Interview Highlights: Pfizer, Bristol Myers Squibb, Sanofi-Aventis and Merck
Zacks.com releases the latest Analyst Interview. Today ’ s interview is with senior analyst Jason Napodano, who discusses Pfizer (... [more]

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium
Bristol-Myers Squibb Company ( BMY ) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) approved updated l... [more]

ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company ( BMY ) announced that ABILIFY ® (aripi... [more]

BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir a
MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company BMY today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (en... [more]

Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. MEDX and Bristol-Myers Squibb Company BMY today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay the Biologics... [more]

Stent Suppliers Look To Reverse Yearlong Slide
CNNMoney.com:  - Mar 20, 2008 Plavix is a blood thinner from Sanofi-Aventis (NYSE:SNY) SNY and Bristol-Myers Squibb ( NYSE:BMY PR) ( NYSE:BMY ) BMY . You take this medication for a minimum ...

XTL Biopharmaceuticals (XTLB) Announces Licensing of its Pre ...
StreetInsider.com (subscription): XTL Biopharmaceuticals (XTLB) Announces Licensing of its Pre ... , MI - Mar 20, 2008 ... ( NYSE: BMY ), where he was responsible for Bristol-Myers Squibb's antiviral drug discovery efforts, including their Hepatitis C and B and

Analyst Touts ImClone Lung Cancer Data
Forbes: , NY - Mar 19, 2008 ImClone receives a royalty on Erbitux sales through partnerships with Bristol-Myers Squibb Co. ( nyse: BMY - news - people ) and German drug maker Merck ...

BellwetherReport.com Free Analyst Review for AUY, BMY, MF and GS
Web Services Journal: , NJ - Mar 19, 2008 ... market activity and position of Bristol-Myers Squibb ( NYSE: BMY ), Yamana Gold (NYSE: AUY), MF Global (NYSE: MF) and Goldman Sachs Group (NYSE: GS). ...

Cramer on BloggingStocks: Financial fixation can cost you
BloggingStocks:  - Mar 18, 2008 Or how about the story that Bristol-Myers ( NYSE: BMY ) (Cramer's Take) might sell its baby-food business for a big chunk of change, another $6 billion. ...

Ardea Biosciences HIV Treatment Is Meeting Midstage Clinical Trial ...
Trading Markets (press release): Ardea Biosciences HIV Treatment Is Meeting Midstage Clinical Trial ... , CA - Mar 17, 2008 s ( NYSE: BMY | news | PowerRating | PR Charts ) Sustiva. Ardea Biosciences is focused on the discovery and development of small-molecule thera

Bristol-Myers spent $5.3M on lobbying
CNNMoney.com:  - Mar 17, 2008 ( NYSE:BMY PR) ( NYSE:BMY ) spent $5.3 million last year lobbying the federal government on health care issues. The New York-based company lobbied on its own ...

Cramer: Pfizer undervalued
Blogging Stocks:  - 1 hour ago ... with a 24.4 P/E ratio, Eli Lilly & Co (NYSE: LLY) at 27.55 times earnings and Bristol-Myers Squibb ( NYSE: BMY ), trading at nearly 37 times earnings. ...

Bristol-Myers Stops Spinning in Place
Motley Fool:  - 7 hours ago Last week, pharmaceutical giant Bristol-Myers Squibb ( NYSE: BMY ) released first-quarter financial results that showed its top line is finally starting to ...

FDA Approves Labeling Update For ORENCIA® (abatacept) To Inhibit ...
Medical News Today (press release): FDA Approves Labeling Update For ORENCIA® (abatacept) To Inhibit ... , UK - 21 hours ago Bristol-Myers Squibb Company ( NYSE: BMY ) announced that the US Food and Drug Administration (FDA) has approved an update to the ORENCIA® (abatac

FDA approves labeling update for Orencia for rheumatoid arthritis
SpiritIndia: , India - 4 hours ago Bristol-Myers Squibb Company ( NYSE: BMY ) announced that the US Food and Drug Administration (FDA) has approved an update to the ORENCIA® (abatacept) product ...

Bristol-Myers (BMY) and Pfizer (PFE) in Collaboration
StreetInsider.com (subscription): , MI - 2 hours ago Bristol-Myers Squibb Company ( NYSE: BMY ) and Pfizer Inc (NYSE: PFE) announced a worldwide collaboration to develop and commercialize apixaban, ...

Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration ...
PR Newswire (press release): Bristol- Myers Squibb Company ( NYSE: BMY ) and Pfizer Inc (NYSE: PFE) ("companies") today announced a ...

FDA Approves Labeling Update for Orencia (abatacept) to Inhibit ...
PharmaLive.com (press release): Bristol-Myers Squibb Company ( NYSE: BMY ) announced that the US Food and Drug Administration (FDA) has approved an update ...

Gilead's Sales are Galloping Ahead
Motley Fool:  - 14 hours ago This is what has happened with Bristol-Myers' ( NYSE: BMY ) and Gilead's HIV treatments, Sustiva and Truvada, respectively, which have been combined in the ...

Monday Market Rap: BOL, BMY, INTC, MO & BOL
Blogging Stocks:  - 7 hours ago Among the stocks that made it onto the most active options list today were Bristol-Myers Squibb ( NYSE: BMY ) with the January 32.50 calls (WBMAZ) moving ...

3 More Kings of Cash
Motley Fool: ... Viread, and Emtriva), lengthy patent protection, and potent partnership with Bristol-Meyers Squibb ( NYSE: BMY ) should keep its canons stuffed with cash. ...

Zacks Analyst Blog Highlights: Tweeter, Best Buy, Gilead Sciences ...
Business Wire (press release): Zacks Analyst Blog Highlights: Tweeter, Best Buy, Gilead Sciences ... , CA - 4 hours ago ... non-nucleoside reverse transcriptase inhibitor manufactured by Bristol-Myers Squibb ( NYSE: BMY ). Atripla was launched in the US at the end

Bristol-Myers Squibb to Announce Results for the First Quarter of ...
PR Newswire (press release): Bristol-Myers Squibb Company ( NYSE: BMY ) will announce results for the first quarter of 2007 on Thursday, ...

Data Available From Erbitux® Phase III Study In First-Line ...
Medical News Today (press release): Data Available From Erbitux® Phase III Study In First-Line ... , UK - 7 hours ago ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company ( NYSE: BMY ) today announced that a Phase III study of ERBITUX® (Cetuximab)

Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R ...
PR Newswire (press release): Bristol-Myers Squibb Company ( NYSE: BMY ) today announced new results of the BARACLUDE(R) (entecavir) resistance ...

CEOs' $1 billion golden boot mark
Blogging Stocks: which triggered a $15.5 ...

ImClone Steps to the Front
MSNBC: ImClone's only marketed drug is the cancer treatment Erbitux, which is partnered with Bristol-Myers Squibb ( NYSE: BMY ). Currently Erbitux is indicated as a ...

Medarex Not Monkeying Around
Motley Fool: one of its many partnerships and licensing agreements. ...

Hana names Leon Rosenberg board chairman
San Jose Business Journal (Subscription): , CA - 5 hours ago He is former head of the pharmaceutical research institute at Bristol-Myers Squibb ( NYSE:BMY ) and former dean of the Yale University School of Medicine. ...

Newspaper wrap-up 3-27-07: Wal-Mart looking to acquire J. Sainsbury
Blogging Stocks:  - 11 hours ago ... Sanofi-Aventis ADS (NYSE: SNY), and Gerard Le Fur, the CEO of Sanofi, over whether to acquire Bristol-Myers Squib Company ( NYSE: BMY ) for $54 billion. ...

From Wall Street, a warning about cancer-drug prices
San Diego Daily Transcript (subscription): ( NYSE: BMY ), was introduced at $10000 a month. That was about $40000 for the course of treatment for the average late-stage colorectal-cancer patient for ...

Bristol-Myers Squibb Names Michael Grobstein to Board of Directors
Drug Newswire (press release): Bristol-Myers Squibb Company ( NYSE:BMY ) announced today that its Board of Directors has elected Michael ...

Great Comebacks(R) Program Announces 2006 National Award Winners
Drug Newswire (press release): ... a world-leading manufacturer of ostomy and wound care products with a heritage of caring about patients, is a Bristol-Myers Squibb Company ( NYSE:BMY ) . ...

Positive Catalysts Seen For Lilly
Forbes: , NY - 7 hours ago ... a money-making blood thinner produced by Bristol-Myers Squibb ( nyse: BMY - news - people ) and Sanofi-Aventis (nyse: SNY - news - people ). ...


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright © 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts